2. Search Result
Search Result
Results for "

Meis1

" in MedChemExpress (MCE) Product Catalog:

25

Inhibitors & Agonists

2

Antibodies

6

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15227
    EPZ004777
    Maximum Cited Publications
    10 Publications Verification

    		 Histone Methyltransferase Apoptosis Inflammation/Immunology Cancer
    EPZ004777 is an effective and selective DOT1L inhibitor, with IC50 being 0.4 nM. EPZ004777 reduces the levels of H3K79me2 and H3K79me1, significantly down-regulating the expression of HOXA9 and MEIS1. EPZ004777 selectively inhibits the proliferation of MLL rearrangement cells and promotes the differentiation and subsequent apoptosis (apoptosis) of leukemia cells. EPZ004777 can be used for the study of leukemia [1] .
    EPZ004777
  • HY-156794
    Enzomenib

    DSP-5336

    		 Epigenetic Reader Domain FLT3 Cancer
    Enzomenib (DSP-5336) is an orally active Menin inhibitor (IC50=1.4 nM, Kd=6.0 nM). Enzomenib disrupts the interaction between Menin and KMT2A/MLL fusion proteins, specifically inhibits the expression of leukemia driver genes such as HOX/MEIS1, and upregulates ITGAM. Enzomenib effectively induces cell differentiation, inhibits tumor cell proliferation, and suppresses primitive cell colony formation. Enzomenib reduces disease burden and prolongs survival, but causes adverse reactions including differentiation syndrome and QTc interval prolongation. Enzomenib is used for research on relapsed/refractory acute myeloid leukemia, acute lymphoblastic leukemia, and other hematologic malignancies with mixed lineage leukemia (MLL) rearrangements or NPM1 mutations [1] .
    Enzomenib
  • HY-15222
    Menin-MLL inhibitor MI-2
    4 Publications Verification

    		 Epigenetic Reader Domain Apoptosis Cancer
    Menin-MLL inhibitor MI-2 is a competitive and selective Menin-MLL interaction inhibitor with an IC50 value of 446 nM and a Ki value of 158 nM. Menin-MLL inhibitor MI-2 downregulates the expression of target genes such as HOXA9 and MEIS1, inhibits proliferation of leukemia cells and induces apoptosis and differentiation. Menin-MLL inhibitor MI-2 is proming for rasearch of MLL-rearranged acute leukemias (e.g., AML, ALL) [1].
    Menin-MLL inhibitor MI-2
  • HY-172416
    Balomenib

    ZE63-0302

    		 Epigenetic Reader Domain Cancer
    Balomenib (ZE63-0302) is an orally bioavailable menin-KMT2A interaction inhibitor. Balomenib disrupts menin-KMT2A binding, reverses aberrant HOX gene expression. Balomenib inhibits Meis1 mRNA expression in KMT2A-rearranged acute myeloid leukemia cells. Balomenib can be used for the research of leukemia [1].
    Balomenib
  • HY-RS08325
    MEIS1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    MEIS1 Human Pre-designed siRNA Set A contains three designed siRNAs for MEIS1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    MEIS1 Human Pre-designed siRNA Set A
    MEIS1 Human Pre-designed siRNA Set A
  • HY-134258
    MEISi-1

    		HOXA Cardiovascular Disease Others Cancer
    MEISi-1 is a homeodomain inhibitor of small molecule MEIS1 protein. MEISi-1 significantly inhibited the activity of luciferase reporter genes containing MEIS binding sites (TGACAG) and induced self-renewal of mouse and human HSCS in vitro and in vivo. MEISi-1 can be used for research in blood diseases, heart regeneration and cancer [1].
    MEISi-1
  • HY-15227A
    EPZ004777 hydrochloride
    Maximum Cited Publications
    10 Publications Verification

    		 Histone Methyltransferase Apoptosis Inflammation/Immunology Cancer
    EPZ004777 hydrochloride is an effective and selective DOT1L inhibitor, with IC50 being 0.4 nM. EPZ004777 hydrochloride reduces the levels of H3K79me2 and H3K79me1, significantly down-regulating the expression of HOXA9 and MEIS1. EPZ004777 hydrochloride selectively inhibits the proliferation of MLL rearrangement cells and promotes the differentiation and subsequent apoptosis (apoptosis) of leukemia cells. EPZ004777 hydrochloride can be used for the study of leukemia [1] .
    EPZ004777 hydrochloride
  • HY-132870
    MEIS-IN-2

    		HOXA Others
    MEIS-IN-2 is a myeloid ecotropic viral integration site 1 (MEIS1) inhibitor.
    MEIS-IN-2
  • HY-134259
    MEISi-2

    		HOXA Cancer
    MEISi-2 is a selective inhibitor of MEIS, a key regulator of hematopoietic stem cell (HSC) self-renewal. MEISi-2 is developed for the research of cardiac injuries, hematopoiesis issues, bone marrow transplantations, and cancer [1].
    MEISi-2
  • HY-RS25706
    Meis1 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Meis1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Meis1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Meis1 Rat Pre-designed siRNA Set A
    Meis1 Rat Pre-designed siRNA Set A
  • HY-RS19217
    Meis1 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Meis1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Meis1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Meis1 Mouse Pre-designed siRNA Set A
    Meis1 Mouse Pre-designed siRNA Set A
  • HY-155797
    (S)-Bleximenib

    (S)-JNJ-75276617; (S)-Menin-MLL inhibitor 24

    		 Drug Isomer HOXA Cancer
    (S)-Bleximenib (Compound 28) ((S)-JNJ-75276617) is an isoform of Bleximenib (HY-148669). (S)-Bleximenib shows an IC50 greater than 1 μM in the MEIS1 mRNA expression assay. (S)-Bleximenib can be used in the research of acute myeloid leukemia [1].
    (S)-Bleximenib
  • HY-160018
    BAY-155

    		Epigenetic Reader Domain Cancer
    BAY-155 is a potent and selective menin-MLL tool inhibitor, with an IC50 of 8 nM. BAY-155 leads to a strong expression down-regulation of the MEIS1 gene and up-regulation of CD11b and MNDA genes. BAY-155 shows anti-proliferative effects in AML/ALL (acute myeloid/lymphoblastic leukemia) models [1].
    BAY-155
  • HY-178172
    AF9/ENL-DOT1L PPI-IN-1

    		Histone Methyltransferase c-Myc Epigenetic Reader Domain HOXA Cancer
    AF9/ENL-DOT1L/AF4 PPI-IN-1 is a potent AF9/ENL and histone methyltransferase DOT1L/AF4 protein-protein interactions (PPI) inhibitor. AF9/ENL-DOT1L/AF4 PPI-IN-1 can inhibit the AF9-DOT1L (IC50 = 1.5 μM), AF9-AF4 (IC50 = 1 μM), ENL-AF4 (IC50 = 1.2 μM) interactions. AF9/ENL-DOT1L/AF4 PPI-IN-1 can suppress the expression of Mixed lineage leukemia (MLL) target genes Myc and Meis1 and selectively block the proliferation of MLL-r and several other leukemia cells. AF9/ENL-DOT1L/AF4 PPI-IN-1 exhibits significant antitumor activities in a mouse model of MLL-r leukemia without overt toxicities. AF9/ENL-DOT1L/AF4 PPI-IN-1 can be used for the study of MLL-r leukemia [1].
    AF9/ENL-DOT1L PPI-IN-1
  • HY-15222A
    Menin-MLL inhibitor MI-2 dihydrochloride

    		Epigenetic Reader Domain Apoptosis Cancer
    Menin-MLL inhibitor MI-2 dihydrochloride is a competitive and selective Menin-MLL interaction inhibitor with an IC50 value of 446 nM and a Ki value of 158 nM. Menin-MLL inhibitor MI-2 dihydrochloride downregulates the expression of target genes such as HOXA9 and MEIS1, inhibits proliferation of leukemia cells and induces apoptosis and differentiation. Menin-MLL inhibitor MI-2 dihydrochloride is proming for rasearch of MLL-rearranged acute leukemias (e.g., AML, ALL) [1].
    Menin-MLL inhibitor MI-2 dihydrochloride
  • HY-155526
    FY-21

    		Histone Demethylase Cancer
    FY-21 is a selective inhibitor of LSD1 (IC50=340 nM), with anti-proliferation and anti-colony formation activities. FY-21 enhances p53 expression, down-regulates HOXA9 and MEIS1 expression. FY-21 also induces leukemia cell differentiation to exhibts antitumor activity [1].
    FY-21
  • HY-186044
    Menin-MLL-IN-36

    		Epigenetic Reader Domain Metabolic Disease Cancer
    Menin-MLL-IN-36 (compound 398) is an inhibitor of menin/MLL protein/protein interaction with an IC50 value of 0.043 μM in MEIS1 mRNA expression. Menin-MLL-IN-36 can be used in the research of cancer, myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), and diabetes [1].
    Menin-MLL-IN-36
  • HY-186043
    Menin-MLL-IN-35

    		Epigenetic Reader Domain Metabolic Disease Cancer
    Menin-MLL-IN-35 (compound 286) is an inhibitor of menin/MLL protein/protein interaction with an IC50 value of 0.096 μM in MEIS1 mRNA expression. Menin-MLL-IN-35 can be used in the research of cancer, myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), and diabetes [1].
    Menin-MLL-IN-35
  • HY-160733
    Menin-MLL-IN-32

    		Epigenetic Reader Domain Cancer
    Menin-MLL-IN-32 (compound 51) is a Menin-MLL interaction inhibitor with an IC50 of 0.042 nM in HTRF assay. Menin-MLL-IN-32 inhibits MEIS1 mRNA expression with an IC50 of 11 nM. Menin-MLL-IN-32 shows anti-proliferative effects, with IC50 values of 8 nM, 24 nM and 1900 nM for MOLM14 cells, OCI-AML3 cells and KO-52 cells, respectively. Menin-MLL-IN-32 can be used for the study of leukemia [1].
    Menin-MLL-IN-32
  • HY-RS27893
    Mei1 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others
    Mei1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Mei1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Mei1 Rat Pre-designed siRNA Set A
    Mei1 Rat Pre-designed siRNA Set A
  • HY-RS08319
    MEI1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    MEI1 Human Pre-designed siRNA Set A contains three designed siRNAs for MEI1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    MEI1 Human Pre-designed siRNA Set A
    MEI1 Human Pre-designed siRNA Set A
  • HY-122698
    CCI-007

    		Apoptosis Cancer
    CCI-007 is a small molecule with cytotoxic activity against infant leukemia with MLL rearrangements, with IC50 values of 2.5-6.2 μM in sensitive cells [1].
    CCI-007
  • HY-115619
    EPZ004777 formate

    		Histone Methyltransferase Apoptosis Cancer
    EPZ004777 formate is an effective and selective DOT1L inhibitor, with IC50 being 0.4 nM. EPZ004777 formate reduces the levels of H3K79me2 and H3K79me1, significantly down-regulating the expression of HOXA9 and MEIS1. EPZ004777 formate selectively inhibits the proliferation of MLL rearrangement cells and promotes the differentiation and subsequent apoptosis (apoptosis) of leukemia cells. EPZ004777 formate can be used for the study of leukemia [1] .
    EPZ004777 formate
  • HY-156794A
    Enzomenib enantiomer

    DSP-5336 enantiomer

    		 Drug Isomer FLT3 Epigenetic Reader Domain Cardiovascular Disease Cancer
    Enzomenib enantiomer (DSP-5336 enantiomer) is an enantiomer of Enzomenib (HY-156794). Enzomenib (DSP-5336) is an orally active Menin inhibitor (IC50=1.4 nM, Kd=6.0 nM). Enzomenib disrupts the interaction between Menin and KMT2A/MLL fusion proteins, specifically inhibits the expression of leukemia driver genes such as HOX/MEIS1, and upregulates ITGAM. Enzomenib effectively induces cell differentiation, inhibits tumor cell proliferation, and suppresses primitive cell colony formation. Enzomenib reduces disease burden and prolongs survival, but causes adverse reactions including differentiation syndrome and QTc interval prolongation. Enzomenib is used for research on relapsed/refractory acute myeloid leukemia, acute lymphoblastic leukemia, and other hematologic malignancies with mixed lineage leukemia (MLL) rearrangements or NPM1 mutations [1] .
    Enzomenib enantiomer
  • HY-RS21374
    Mei1 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Mei1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Mei1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Mei1 Mouse Pre-designed siRNA Set A
    Mei1 Mouse Pre-designed siRNA Set A

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: